Company
About us
Acticor Team
Board of Directors
investors & Partners
Prizes & Awards
Our Product
Our product: Glenzocimab
GPVI / GLENZOCIMAB in brief
in acute ischemic stroke
⮑ Positive results actimis study
in other indications
Pipeline
About stroke
Key figures
What is a stroke?
Media
Press Releases
Publications
Media Coverage
Events
Investors
Welcome
Corporate Presentation
Share Overview
Shareholders' Meeting
Regulated Information
Financial Agenda
COntact
Investors
Press Releases
July 21, 2022
Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke
